Neuroscience

Neurodegeneration

Progressive loss of neuronal structure and function, as seen in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease.

In Depth

The endocannabinoid system is dysregulated in multiple neurodegenerative diseases. CB1 receptor density is reduced in Alzheimer's and Huntington's disease. CB2 receptors are upregulated on activated microglia in neurodegenerative lesions. Cannabinoids have shown neuroprotective effects in animal models of Alzheimer's (reducing amyloid-β and tau pathology), Parkinson's (protecting dopaminergic neurons), and ALS. Clinical trials are ongoing but results have been mixed, and no cannabinoid is approved for any neurodegenerative indication.

Further Reading